Results 181 to 190 of about 33,233,550 (381)

Mechanisms and kinetic assays of aminoacyl‐tRNA synthetases

FEBS Letters, EarlyView.
Igor Zivkovic, Morana Dulic, Ita Gruic‐Sovulj   +2 more
wiley   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Establishing the Minimum Clinically Significant Difference (MCID) and the Patient Acceptable Symptom Score (PASS) for the Hospital Anxiety and Depression Scale (HADS) in Patients with Rotator Cuff Disease and Shoulder Prosthesis. [PDF]

J Clin Med, 2023
Longo UG, Papalia R, De Salvatore S, Marinozzi A, Piergentili I, Lalli A, Bandini B, Franceschetti E, Denaro V.   +8 more
europepmc   +1 more source

Confidence intervals with birth defects surveillance data: A tempest in a teapot or honestly significant differences of opinion? [PDF]

, 2003
Pamela Costa, Russell S. Kirby
openalex   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

No significant difference: use of statistical methods for testing equivalence in clinical veterinary literature [PDF]

, 2003
Robert Christley, S. W. J. Reid
openalex   +1 more source

Biological and technical complexities in analyzing extracellular vesicle immune interactions in B‐cell malignancies

FEBS Letters, EarlyView.
Daniel Bachurski, Michael Hallek
wiley   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Explanation of significant differences for the TNX groundwater operable unit

, 1997
E. Palmer
openalex   +2 more sources

The Venue of Testing (In-Home [H] versus Attended [A]) Does not Produce any Significant Difference in Test Results or Clinical Outcomes in Patients With Obstructive Sleep Apnea (OSA [PDF]

, 2003
Richard J. Pisani, Jeffrey R. Smoots, Sid Kapnadak, Beth Bowers   +3 more
openalex   +1 more source